End-stage Heart Failure
Conditions
Keywords
LVAD, pulsatility index, Von Willebrand Factor
Brief summary
The primary objective of this study is to determine whether preserved pulsatility for patients supported by CF-LVAD (continuous flow Left Ventricular Assist Device) is associated with less acquired deficiency of the Von Willebrand factor, a blood glycoprotein involved in hemostasis.
Detailed description
Implantation of LVADs (Left Ventricular Assist Device) is a medium to long-term therapeutic option for patients with end-stage heart failure and isolated left ventricular dysfunction. Nevertheless, LVADs use remain limited by the frequency of their adverse effects, most of which being unpredictable. In the literature, loss of pulsatility seems to be associated with CF-LVADs complications, including bleeding. Accordingly, the primary objective of this study is to determine whether patient's preserved pulsatility is associated with less acquired deficiency of the Von Willebrand factor (VWF), a blood glycoprotein involved in hemostasis. This deficiency, characterized by a decrease or absence of VWF High Molecular Weight Multimers (HMWMs), is present to varying degrees in almost all patients with LVADs and is a major risk factor for bleeding complications in these patients. Pulsatility is estimated by the patient's blood pressure differential, measured 1) at discharge from the operating room (=transfer to care), 2) at discharge from care (=transfer to his or her room), 3) at discharge from the hospital (=transfer to rehabilitation), and then at each follow-up visit up to 6 months post-implantation. The primary endpoint is to determine whether a preserved pulsatility is associated with less acquired deficiency of the Von Willebrand factor ratio of High Molecular Weight Multimers (HMWMs).
Interventions
OTHERBlood sampling
For 10 visits (out of the 12 of the protocol), \ 40 ml of blood is sampled for research purposes in addition to care sampling.
Sponsors
ICAN Nutrition Education and Research
University Hospital, Lille
Institut National de la Santé Et de la Recherche Médicale, France
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients over 18 years of age 2. Patients for whom a decision to implant a left-sided monoventricular assist has been retained after discussion in the RCP of heart failure, transplantation and circulatory assistance (whatever the therapeutic strategy envisaged: waiting for transplantation, recovery or destination therapy). 3. Patients affiliated to a social security system (beneficiaries or beneficiaries entitled to benefits, excluding AME) 4. Signature of an informed consent by the patient or by the trusted person, or a close relative, if the patient is not able to do so
Exclusion criteria
1. Heart transplant patients 2. Patients who already had LVAD 3. Chronic renal failure patients on dialysis 4. Patients refusing to give informed consent 5. Patients deprived of liberty or under legal protection (guardianship, curators) 6. Pregnant or breastfeeding women 7. Ongoing participation in another intervention research protocol except LEVOECMO project (NCT04728932) and ANCHOR project (NCT04184635)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Von Willebrand factor high molecular weight multimers (HMWM) ratio | 30 days after LVAD IMPLANTATION | Comparison of Von Willebrand factor high molecular weight multimers (HMWM) ratio at LVAD pre-implantation and at day 30. Measure of an correlation between preserved pulsatility and the HMWM ratio evolution during the first month after implantation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Post-operative right ventricular failure | 6 months | Track record of patients undergoing right ventricular failure, identified by: * Elevation of central venous pressure (CVP) \>16 mmHg by direct or echocardiographic measurement (inferior vena cava diameter \>20 mm and respiratory variations \<50%) for more than 48 hours * and at least one of the following signs of hemodynamic failure persisting for more than 48 hours: * Increased inotropic score * Hyperlactatemia \>3 mmol/l * Hepatic cytolysis: increase in AST and/or ALT by a factor of 3 or more after implantation * Degradation of renal function (AKIN grade 2: creatinine elevation \> 50% compared with before explantation and diuresis \< 0.5 ml/kg/24h for 12 hours) * Implantation of right temporary circulatory support (ECMO) |
| Platelet dysfunction | 6 months | Platelet dysfunction defined by a significant increase in circulating levels of p-selectin and glycocalicin between pre- and post-implantation |
| Post-operative transient or permanent ischemic attack | 6 months | Track record of patients undergoing ischemic attack (between 24 hours and 6 months post-operative) as assessed per INTERMACS definition |
| Vascular endothelium dysfunction | 6 months | Vascular endothelial dysfunction defined by a significant increase in circulating levels of syndecan, thrombomodulin, TFPI and PAI-1 between pre- and post-implantation |
| Severe postoperative gastrointestinal bleeding | 6 months | Track record of patients undergoing gastrointestinal bleeding, identified by a decreased hemoglobin level associated with chronic iron deficiency anemia of unexplained cause and melena or bleeding demonstrated by exploration of the gastrointestinal tract by esophageal endoscopy, colonoscopy, or endoscopic videoscopy and resulting in any of the following: * Death * Re-operation * Hospitalization * An erythrocyte transfusion defined as: * Within 7 days of implantation : * Patients weighing 50 kg or more: ≥ 4U of packed red blood cells in a 24-hour period. * Patients weighing less than 50 kg: ≥ 20 mL/kg of packed red blood cells over a 24-hour period * After 7 days post-implantation : any transfusion of packed red blood cells. |
| Evolution of immune responses | 6 months | Monthly phenotyping of monocytes and T cells |
| Aortic valve fusion | 6 months | Monthly echographic evaluation |
| Aortic valve insufficiency | 6 months | Monthly echographic evaluation |
| Evaluation of cardiac recovery | 6 months | Monthly exercise stress test evaluation (starting 2 months post-operative) |
| Prolonged systemic inflammatory reaction syndrome | 6 months | Monthly measures of following circulating inflammatory factors : TNFα et β, NF kappab, TGF α /β1/β2,IFNγ et β, IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL12-P70, IL-17, IL17A et F,CX3CL1 (fractalkine),MCP-1(CCL2), MIP-1 (CCL3), MIP-1β(CCL4), MIP-3-beta (CCL19), 6Ckine(CCL21), MCD (CCL22) Myostatin, calveolin-1. |
Countries
France
Outcome results
None listed